Mein Warenkorb

HLA-A*0201 | B2M | p53 (RMPEAAPPV)

Produktanfrage

HLA-A*0201 | B2M | p53 (RMPEAAPPV) Molekülhintergrund

TP53 has been recognized as a tumor suppressor. 50% of cancers carry a TP53 mutation while many others affect other pathway components. High-copy numbers of WT p53 peptide-MHC class I complexes were detected on tumor cells as compared to low copies on normal cells. The Human HLA-A*0201 p53 (GLAPPQHLIRV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and GLAPPQHLIRV peptide of the p53.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
RisuteganibALG-1001; AM011; AM-011(Allegro Ophthalmics)Phase 1 ClinicalAllegro Ophthalmics LlcDiabetic macular oedema; Geographic Atrophy; Macular Degeneration; Diabetic Retinopathy
Details
  • Produktanfrage
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns